
Halozyme Therapeutics has announced that Johnson & Johnson was granted accelerated approval from the US Food and Drug Administration (FDA) for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), which is co-formulated with Enhanze, as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody.
The indication does not include patients with oropharyngeal squamous cell carcinoma that is HPV-associated.
It is the first approval of a dual-targeted therapy in this setting, simultaneously targeting epidermal growth factor receptor (EGFR)- and mesenchymal-epithelial transition (MET).


